



The TIMI Trials

JUMBO-TIMI 26

OBJECTIVE: To evaluate the efficacy and safety of prasugrel, a novel thienopyridine, compared to clopidogrel in patients undergoing PCI

1. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E for the JUMBO – TIMI 26 investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention; Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO) – TIMI 26 trial. *Circulation* 2005;111:3366-73.
2. Bonaca MP, Morrow DA, Sabatine MS, Murphy SA, Scirica BM, Rifai N, Antman EM, Braunwald E. Clinical correlates and impact of aspirin on the inflammatory response to percutaneous coronary intervention: Results from TIMI 26. *Circulation* 2005;112:II:322.
3. Wiviott SD, Morrow DA, Sabatine MS, Murphy SA, Winters KJ, Antman EM, Braunwald E. Prasugrel suppresses the early rise of sCD40 ligand levels following PCI compared to clopidogrel: A JUMBO-TIMI 26 substudy. *Circulation* 2005;112:II:432.
4. Bonaca MP, Wiviott SD, Sabatine M, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA. Hemodynamic significance of peri-procedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease from the JUMBO-TIMI 26 trial. *Am J Cardiol* 2007;99:344-348.